FDA Clearance Tracker · P890064-S032
DIGENE HYBRID CAPTURE 2 (HC2) HPV DNA TESTS
Last checked: Nov 20, 2026Latest source record: May 29, 2015 (this decision)Source: openFDAMethods & limitations
Decided
May 29, 2015
Approved
Time to decision
31 days
Received Apr 28, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P890064-S032
- Device name
- DIGENE HYBRID CAPTURE 2 (HC2) HPV DNA TESTS
- Applicant
- Qiagen Gaithersburg, Inc.
- Applicant location
- Germantown, MD
- Received
- Apr 28, 2015
- Decided
- May 29, 2015
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P890064
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR A MANUFACTURING SITE LOCATED IN PENANG, MALAYSIA.
Source documents
Other decisions for Qiagen Gaithersburg, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.